Tag - NASDAQGS:TRIB

Sturm, Ruger & Co. (NYSE: RGR), Triad Guaranty Inc. (Nasdaq: TGIC) and Barrett Business Services, Inc. (Nasdaq: BBSI) are among the biggest percentage losers in Thursday's trading among companies with market capitalizations under $750 million.

Here are today's biggest percentage losers:

CoolcatReport.com publisher Kevin Kennedy uses a proprietary trading and screening system, based in large part on momentum. For example, the stocks that make his buy list must be trading above their closes of 3, 6 and 12 months ago. In addition, they must have made new 52-week highs in the past two months.

Generally, Kennedy prefers stocks that have made new highs, have pulled back in a consolidation pattern, and are then poised to again move to new highs.

This basic strategy is applied to a wide range of stock ideas through his multiple Coolcat newsletter services. Small caps are featured in his Coolcat Explosive Small Cap Growth Stock Report.

“This batch of stocks is hanging out just above its 50-day moving average, offering some interesting entries with decent risks,” Kennedy says. “All have put earnings season to bed and appear well-positioned to move up from here.”

Passing Kennedy’s screening process is a trio of biotech stocks. Metabasis Therapeutics Inc. (Nasdaq: MBRX), says Kennedy, has a “promising pipeline” of preclinical and clinical product candidates targeting metabolic diseases such as diabetes, hyperlipidemia and obesity.

He notes that first-quarter revenues jumped 252% to $3.4 million, which included a $1.8-million upfront license fee received from Schering-Plough Corp. (NYSE: SGP) and license fee and sponsored research revenue from its hepatitis C collaboration with Idenix Pharmaceuticals Inc. (Nasdaq: IDIX).

The company – with a market cap of $243 million -- had $71.3 million in cash, cash equivalents and securities at the end of March, Kennedy notes.

Meanwhile, BioImaging Technologies Inc. (Nasdaq: BITI), with a market cap of $78 million, offers services to support the pharmaceutical, biotech and medical device industries in product development.

Shares of Irish pharmaceutical company Trinity Biotech plc (Nasdaq: TRIB) posted a new 52-week high this morning on news of an increase in first-quarter revenue and profit.

Revenues for the quarter ended March 31 were $36.7 million, an increase of 48.5% from $24.7 million a year earlier, the company said before the market open.  The quarterly profit was $2.9 million, up 135% from $1.24 million in the first quarter of 2006.  Earnings per share were $0.15, above Wall Street’s forecast of $0.10 per share.  Earnings were $0.08 per share in the first three months of 2006.

These are the biggest percentage gainers at 10:07 ET among companies with market capitalizations under $500 million: